UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________ FORM 10-QSB ______________  [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 [  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d)OF THE EXCHANGE ACT For the transition period from ____________ to____________ Commission File No. 000-24480 SANGUINE CORPORATION (Exact name of small business issuer as specified in its charter)   Nevada95-4347608(State or Other Jurisdiction of(I.R.S. Employer Identification No.)incorporation or organization)  101 East Green Street, #6 Pasadena, California 91105 (Address of Principal Executive Offices)  (626) 405-0079 (Issuers Telephone Number)  N/A (Former name, former address and former fiscal year, if changed since last report)  Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]  Indicate by check mark whether the Issuer is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]  APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS  Not applicable.  Check whether the Issuer filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court.  Yes [  ] No [  ]  1    Not applicable.  APPLICABLE ONLY TO CORPORATE ISSUERS  Indicate the number of shares outstanding of each of the Issuers classes of common equity, as of the latest practicable date: November 15, 2007 - 91,092,825 shares of common stock.  Transitional Small Business Disclosure Format (Check one): Yes [  ] No [X]    PART I - FINANCIAL INFORMATION  Item 1. Financial Statements.  2             SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company)  CONSOLIDATED FINANCIAL STATEMENTS  September 30, 2007 and December 31, 2006  3      SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company)  Consolidated Balance Sheets   ASSETS    September 30,
2007December 31,
2006(Unaudited)CURRENT ASSETSCash$4,697$30,288Prepaid expense516,361-Total Current Assets521,05830,288PROPERTY AND EQUIPMENT, NET745968TOTAL ASSETS$521,803$31,256                            The accompanying notes are an integral part of these consolidated financial statements.  4     SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company)  Consolidated Balance Sheets (Continued)   LIABILITIES AND SHAREHOLDERS EQUITY (DEFICIT)    September 30,
2007December 31,
2006(Unaudited)CURRENT LIABILITIESRelated party payables$2,000$4,000Accounts payable338,266323,370Warrant liability7232,123Accrued compensation34,68878,937Total Current Liabilities375,677408,430Total Liabilities375,677408,430COMMITMENTS AND CONTINGENCIESSHAREHOLDERS EQUITY (DEFICIT)Common stock, 200,000,000 shares authorized   of $0.001 par value, 89,092,825 and 81,683,658 shares
issued and outstanding, respectively89,09381,684Common stock subscribed-27,800Additional paid in capital7,052,6265,873,443Accumulated other comprehensive income (loss)(12,754)(2,570)Deficit accumulated during the development stage(6,982,839)(6,357,531)Total Shareholders Equity (Deficit)146,126(377,174)TOTAL LIABILITIES AND SHAREHOLDERS
EQUITY (DEFICIT)$521,803$31,256          The accompanying notes are an integral part of these consolidated financial statements.   5     SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company) Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) For the Three Months Ended
September 30,For the Nine Months Ended
September 30,From Inception of the Development Stage on January 18, 1990 through September 30,20072006200720062007REVENUES$-$500$-$5,563$181,762OPERATING EXPENSESProfessional fees6,610115,156162,276145,0543,058,454Research and
Development-109,11272,182244,2901,971,831Selling, general and
Administrative111,347(1,620)238,69798,0112,840,329Total Operating Expenses117,957222,648473,155487,3557,870,614LOSS FROM OPERATIONS(117,957)(222,648)(473,155)(481,792)(7,688,852)OTHER INCOME (EXPENSE)Interest income13442911,92939,356Interest expense----(667,986)Loss on cash deposit----(10,020)Warrant expense(76,122)-(152,244)-(152,244)Gain on settlement of
Debt----1,496,907Total Other Income (Expense)(76,109)442(152,153)1,929706,013NET INCOME (LOSS)(194,066)(222,206)(625,308)(479,863)(6,982,839)  The accompanying notes are an integral part of these consolidated financial statements.  6      SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company) Consolidated Statements of Operations and Other Comprehensive Income (Loss)-continued (Unaudited)  For the Three Months Ended
September 30,For the Nine Months Ended
September 30,From Inception of the Development Stage on January 18, 1990 through September 30,20072006200720062007  OTHER COMPREHENSIVE INCOME (LOSS)Loss on foreign currency exchange(7,309)-(10,184)-(12,754)TOTAL COMPREHENSIVE INCOME (LOSS)$(201,375)$(222,206)$(635,492)$(479,863)$(6,995,593)BASIC INCOME (LOSS) PER SHARE$(0.00)$(0.00)$(0.01)$(0.00)DILUTED INCOME PER SHARE$(0.00)$(0.00)$(0.01)$(0.00)WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING BASIC88,488,43081,283,65885,379,90181,009,665WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING-DILUTED88,488,43081,283,65885,379,90181,009,665   The accompanying notes are an integral part of these consolidated financial statements.  7     SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company) Consolidated Statements of Cash Flows (Continued) (Unaudited) For the Nine Months Ended
September 30,From Inception of the Development Stage on January 18, 1990 through September 30,200720062007Net loss$(625,308)$(479,863)$(6,982,839)Adjustments to reconcile net loss to net cash used
by operating activities:Depreciation2242245,356Common stock issued for services373,188143,8123,032,337Contributed capital--520Stock options granted152,244-152,244Stock warrants granted--8,650Interest on beneficial conversion feature--25,000Legal expense related to beneficial conversion feature--3,750Note payable issued for services--727,950Gain on extinguishments of debt--(98,826)Gain on conversions of debt to equity--(1,398,081)Recognition of prepaid expenses and
expenses prepaid with common stock--456,184Changes in assets and liabilities:Increase in accounts payable and related party payables2,711173,533651,699Increase in accrued interest payable--547,279Increase in accrued liabilities--10,125Increase in customer deposits`--45,000Increase (decrease) in warrant liability(1,400)(11,774)723Increase in accrued salaries(44,249)45,249868,563Net Cash Used by Operating Activities(142,590)(128,819)(1,944,366)CASH FLOWS FROM INVESTING ACTIVITIESCash paid for fixed assets--(6,100)Net Cash Used by Investing Activities--(6,100)CASH FLOWS FROM FINANCING ACTIVITIESProceeds from warrant conversion100,00020,000524,700Proceeds from notes payable and notes payable-
related party--212,139Payments on notes payable and notes payable 
related party--(9,400)Proceeds from issuance of convertible debentures--40,000Contributed capital--750Common stock issued for cash16,999-1,186,974Net Cash Provided by Financing Activities116,99920,0001,955,163NET INCREASE (DECREASE) IN CASH(25,591)(108,819)4,697CASH AT BEGINNING OF PERIOD30,288159,466-CASH AT END OF PERIOD$4,697$50,647$4,697 The accompanying notes are an integral part of these consolidated financial statements.  8       SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company) Consolidated Statements of Cash Flows (Unaudited) For the Nine Months Ended
September 30,From Inception of the Development Stage on January 18, 1990 through September 30,200720062007   SUPPLEMENTAL SCHEDULE OF CASH FLOW ACTIVITIESCASH PAID FOR:Interest$-$-$-Income taxes$-$-$-NON-CASH ACTIVITIESCommon stock issued for debt conversion$-$-$9,600Equity instruments issued for services rendered$373,188$143,812$3,032,337Contributed capital for interest contributed$-$-$520Interest on beneficial conversion feature$-$-$25,000Legal related to beneficial conversion feature$-$-$3,750Notes payable issued for services$-$-$727,950Common stock issued for prepaid services$-$-$236,284Common stock issued for debt$-$-$2,822,067                    The accompanying notes are an integral part of these consolidated financial statements.    9     SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company) Notes to Consolidated Financial Statements September 30, 2007 and December 31, 2006   NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION  The accompanying unaudited consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted in accordance with such rules and regulations.  The information furnished in the interim consolidated financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim consolidated financial statements be read in conjunction with the Companys most recent audited financial statements and notes thereto included in its December 31, 2006, Annual Report on Form 10-KSB.  Operating results for the three and six months ended September 30, 2007, are not necessarily indicative of the results that may be expected for the year ending December 31, 2007.  NOTE 2 - GOING CONCERN  The Companys financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern.  The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.  If the Company is unable to obtain adequate capital, it could be forced to cease operations.  The Companys management has taken certain steps to maintain its operating and financial requirements in an effort to continue as a going concern until such time as revenues are sufficient to cover expenses.  Future plans include a debt or equity offering for between $1,000,000 and $1,500,000 that should enable the Company to complete the animal testing stage for FDA approval of its product.  However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.  The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations.  The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.   10     SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company) Notes to Consolidated Financial Statements September 30, 2007 and December 31, 2006   NOTE 3 -STOCK OPTIONS AND WARRANTS  A summary of the status of the Companys outstanding stock warrants as of September 30, 2007, and December 31, 2006, and changes during the periods then ended is presented below:  20072006SharesWeighted Average Exercise PriceSharesWeighted Average Exercise PriceOutstanding, beginning of year2,123,115$0.082,843,757$0.15Granted----Expired/Cancelled(150,000)0.125(470,642)0.13Exercised(1,250,000)0.08(250,000)0.08Outstanding end of year723,115$0.082,123,115$0.08Exercisable723,115$0.082,123,115$0.08   OutstandingExercisableRange of Exercise PricesNumber outstanding at September 30, 2007Weighted Average Remaining Contractual LifeNumber Exercisable at September 30,2007$0.08693,115.40693,1150.02830,000.6030,000723,115723,115  A summary of the status of the Companys outstanding stock options as of September 30, 2007, and December 31, 2006, and changes during the periods then ended is presented below:  20072006SharesWeighted Average Exercise PriceSharesWeighted Average Exercise PriceOutstanding, beginning of year-$--$-Granted5,000,0000.06--Expired/Cancelled----Exercised----Outstanding end of year5,000,000$0.06-$-Exercisable5,000,000$0.06-$-   11     SANGUINE CORPORATION & SUBSIDIARY (A Development Stage Company) Notes to Consolidated Financial Statements September 30, 2007 and December 31, 2006   NOTE 3 -STOCK OPTIONS AND WARRANTS (Continued)   OutstandingExercisableRange of Exercise PricesNumber outstanding at September 30, 2007Weighted Average Remaining Contractual LifeNumber Exercisable at September 30,2007$0.065,000,0001.455,000,0005,000,0005,000,000  During the nine months ended September 30, 2007, the Company granted 5,000,000 options to purchase the Companys common stock for an exercise price of $0.06 per share for a period of 24 months beginning in April, 2007.  The options were granted as part of a consulting agreement with LKB Partners, LLC entered into during the second quarter.  The Company valued the options using the Black-Scholes option-pricing model with the following assumptions: dividend yield of zero percent; expected volatility of 75.6%; risk-free interest rate of 4.73%; and expected life of 2 years.  The value of the options was initially recorded as a prepaid expense which is being amortized over the 15 month term of the consulting agreement which expires on June 30, 2008.  NOTE 4 - EQUITY TRANSACTIONS  During the nine months ended September 30, 2007, the Company issued 532,500 shares of common stock for services valued at a range of $0.09-$0.23 per share for a total of $181,188; 1,533,334 shares issued for warrants exercises valued at a range of $0.06-$0.08 per share for a total of $117,000; and 5,000,000 shares issued pursuant to a consulting agreement valued at $0.12 per share for a total of $600,000 of which $480,000 was initially recorded as a prepaid asset and is being amortized over the 15 month term of the consulting agreement.  Common stock issued for services, prepaid services and cash-less option exercises have been accounted for at the fair market value of the securities on the date of issue.  NOTE 5 - SUBSEQUENT EVENTS  Subsequent to the quarter end, the Company issued 2,000,000 shares of common stock for $100,000 as part of a stock purchase agreement.   12      Item 2. Managements Discussion and Analysis or Plan of Operation.  Forward-looking Statements  Statements made in this Quarterly Report which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company, including, without limitation, (i) the Companys ability to raise capital, and (ii) statements preceded by, followed by or that include the words may, would, could, should, expects, projects, anticipates, believes, estimates, plans, intends, targets or similar expressions. Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Companys control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following, general economic or industry conditions, nationally and/or in the communities in which the Company may conduct business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, the Companys ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting the Companys operations, products, services and prices. Accordingly, results actually achieved may differ materially from expected results in these statements.  Forward-looking statements speak only as of the date they are made.  The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements. Plan of Operation  We have not commenced planned principal operations, but have made good progress since the end of fiscal 2005, in formulation and stability testing.  In January, 2005, we were successful in developing improved formulations of our surfactants for PHER-02.  In December, 2006, we completed a pre-IND meeting with the FDA, where Company management presented data to determine an appropriate regulatory path related to PHER-O2.  Our plan of operation for the next 12 months is to complete the preparation and submission of the U.S. FDA New Device Application to support PHER-02 as a synthetic oxygen carrying product.  Our proposed plan of operation is composed of stages, each of which coincides with a specific milestone in the process of developing PHER-O2.  Each stage, and the projected cost of each, is as follows:  Stage A (approximately three-six months): Complete the development of perfluoro-decalin and the synthetic surfactants that make up PHER-O2, manufactured experimental doses in accordance with FDA and overseas regulations and submit data to support a Master Drug Filing.  Estimated cost is not to exceed $500,000, divided as follows: Completed surfactant formulation (done) and the manufacture of sufficient product for testing, (on going); animal safety and efficacy trials through a sub-contractor, (done); and administrative, patent and proprietary right protection and marketing costs,(in process) Optimize stabilized product to support the Master Drug Filing (in process).  Stage B (approximately three-six months): In the second period, we will produce optimal quantities and conduct testing in accordance with FDA and overseas requirements.  During the course of Stage A, we estimate that our increased technical, administrative, sales/marketing and manufacturing requirements will require us to the hire a few additional contractors and/or employees.  Stage C (approximately three-six months): In the third period, we intend to prepare new 510(k) device application with the FDA.  Estimated cost is $1,000,000, to be used as follows: set-up pilot facility, or subcontractor,  13     to manufacture small quantities of PHER-O2 for use in testing and in connection with the New Drug Applications [done], prepare and submit data for use of PHER-O2 as a whole organ transportation medium in support of FDA labeling, and administrative, patent and proprietary right protection and marketing costs, (in process).  These cost estimates are based upon the prior experience of Thomas C. Drees, Ph.D., our President and CEO.  Dr. Drees has more than 33 years experience in the blood industry with Abbott Scientific, Alpha Therapeutics and Sanguine Corporation.  Managements Discussion and Analysis of Financial Condition and Results of Operations  Three Months Ended September 30, 2007, Compared to the Three Months Ended September 30, 2006  Revenues for the quarters ending September 30, 2007, and 2006, were $0 and $500, respectively.  We had no material operations, except the research and development activities related to our subcontracted research and development of our product, PHER-O2.  We realized a total comprehensive loss of $201,375 for the quarter ended September 30, 2007, and a net loss of $222,206 for the quarter ended September 30, 2006.  Most of our expense related to research and development and professional fees in 2006.  For the current three months ended our expenses were primarily administrative costs as well as the costs of issuing stock for services and the granting of options.  Our research and development expenses were $0 for the quarter ended September 30, 2007, compared to $109,112 in the same period of 2006.  We did not have the funds to incur additional research and development expenses during the current quarter.  Subsequent to the quarter ended September 30, 2007, we sold 2,000,000 shares of common stock in connection with a stock purchase agreement for $100,000.  Nine Months Ended September 30, 2007, Compared to the Nine Months Ended September 30, 2006  Revenues for the nine months ended September 30, 2007, and 2006, were $0 and $5,563, respectively.  We had no material operations, except the research and development activities related to our subcontracted research and development of our product, PHER-O2.  We realized a total comprehensive loss of $635,492 for the nine months ended September 30, 2007, and a net loss of $479,863 for the nine months ended September 30, 2006.  Most of our expense related to research and development in 2006.  Our research and development expenses were $72,182 for the nine months ended September 30, 2007, compared to $244,290 in the same period of 2006.  During the nine months ended September 30, 2007, we issued 4,000,000 shares of common stock and granted 5,000,000 options to purchase common stock in connection with a consulting agreement.  Both the shares and stock options have been valued at fair market value as of the date of issuance and grant.  The value of the shares and options was initially recorded as a prepaid expense which is being amortized over the 15 month term of the consulting agreement which expires on June 30, 2008.  For the three months ended September 30, 2007, the Company recognized $172,121 as an expense related to these shares and options.  Subsequent to the quarter ended September 30, 2007, we sold 2,000,000 shares of common stock in connection with a stock purchase agreement for $100,000.  Liquidity  As of September 30, 2007, we had $4,697 in cash and $516,361 in prepaid expenses, with $375,677 in current liabilities.  Subsequent to the quarter ended September 30, 2007, we sold 2,000,000 shares of common stock in connection with a stock purchase agreement for $100,000.  14       We plan to fund our proposed stages of operations by additional private placements of debt or equity securities or a combination of both.  Off-balance sheet arrangements  We had no off-balance sheet arrangements during the quarter ended September 30, 2007.   Item 3(a)T. Controls and Procedures.  Managements annual report on internal control over financial reporting  As of the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our President and Secretary, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our President and Secretary concluded that information required to be disclosed is recorded, processed, summarized and reported within the specified periods and is accumulated and communicated to management, including our President and Secretary, to allow for timely decisions regarding required disclosure of material information required to be included in our periodic Securities and Exchange Commission reports. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and our President and Secretary have concluded that our disclosure controls and procedures are effective to a reasonable assurance level of achieving such objectives. However, it should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. In addition, we reviewed our internal controls over financial reporting, and there have been no changes in our internal controls or in other factors in the last fiscal quarter that has materially affected our internal controls over financial reporting.  However, during our review, our auditors noted a significant deficiency in our internal controls and believe that our methodology for identifying all necessary disclosures could lead to a material misstatement of net income (loss).  We have addressed that weakness and feel that proper application of controls that have been put in place will eliminate such deficiencies in the future.  It should be noted, however, that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote. In addition, we have reviewed our internal controls over financial reporting, and incorporated minor changes necessary during the period covered by this quarterly report.  Changes in internal control over financial reporting  We had no changes in internal control over financial reporting during the period covered by this Quarterly Report.   PART II - OTHER INFORMATION   Item 1. Legal Proceedings.  None; not applicable.   Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.  Recent Sales of Unregistered Securities  During the last three months we did not issued any unregistered securities.  15     Use of Proceeds of Registered Securities  We did not receive any proceeds from the sale of registered securities during the quarter ended September 30, 2007.  Purchases of Equity Securities by Us and Affiliated Purchasers  None; not applicable.   Item 3. Defaults Upon Senior Securities.  None; not applicable.   Item 4. Submission of Matters to a Vote of Security Holders.  None; not applicable.   Item 5. Other Information.  (a)Subsequent to the quarter ended September 30, 2007, we sold 2,000,000 shares of common stock in connection with a stock purchase agreement for $100,000.  (b) Nominating Committee  During the quarterly period ended September 30, 2007, there were no changes in the procedures by which security holders may recommend nominees to our Board of Directors.   Item 6. Exhibits  (a) Exhibits and Index of Exhibits.  None.  31.1 302 Certification of Thomas C. Drees, PH.D  31.2 302 Certification of David E. Nelson  32 Section 906 Certification.     SIGNATURES  In accordance with the requirements of the Exchange Act, the Registrant has caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.  SANGUINE CORPORATION  Date:11/19/07By:/s/Thomas C. DreesThomas C. DreesCEO, President and Chairman of the Board of DirectorDate:11/19/07By:/s/David E. NelsonDavid E. NelsonCFO and Director   16